Songporn Oranratnachai

Overview

Explore the profile of Songporn Oranratnachai including associated specialties, affiliations and a list of published articles.

Snapshot

Articles 9

Citations 41

Followers 0

Related Specialties

Oncology

Biochemistry

Gastroenterology

Top 10 Co-Authors

Thanyanan Reungwetwattana

Narumol Trachu

Ekaphop Sirachainan

Ammarin Thakkinstian

Insee Sensorn

Nanamon Monnamo

Thitiya Dejthevaporn

Amarit Tansawet

Sasivimol Rattanasiri

Khantong Khiewngam

Published In

Front Oncol

BMC Cancer

Cancer Med

J Thorac Oncol

Cancer Rep (Hoboken)

Affiliations

Soon will be listed here.

Recent Articles

Dynamic changes in immune repertoire profiles in patients with stage III unresectable non-small cell lung cancer during consolidation treatment with immunotherapy

Iemwimangsa N, Anantaya D, Oranratnachai S, Thamrongjirapat T, Lumjiaktase P, Teoh V, et al.

BMC Cancer . 2025 Feb; 25(1):333. PMID: 39994571

Background: One-year of immune checkpoint inhibitor (ICI) treatment after concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer (NSCLC) is a standard of care. The precise predictive biomarkers...

Comparison of treatment outcome between first-line combination immunotherapy (anti-PD-L1 or anti-PD1) with or without chemotherapy and chemotherapy alone in advanced non-small cell lung cancer patients in tertiary care hospital

Naratornsirakul D, Chewaskulyong B, Kongkarnka S, Oranratnachai S

Cancer Med . 2024 Jul; 13(14):e70007. PMID: 39030820

Background: Despite promising outcomes of first-line immunotherapy with or without chemotherapy in advanced non-small cell lung cancer (NSCLC), limited accessibility due to reimbursement was remain the problem in low to...

Long-term posttransplant survival outcome following bridging locoregional therapy in hepatocellular carcinoma patients: A systematic review and meta-analysis

Chuncharunee A, Oranratnachai S, Chuncharunee L, Intaraprasong P, Thakkinstian A, Sobhonslidsuk A

JGH Open . 2024 Jul; 8(7):e13111. PMID: 38978769

Aim: Liver transplantation (LT) is essential due to its curative efficacy, but liver-graft shortages have limited its widespread application. Bridging locoregional therapy (LRT) before LT has been performed to prevent...

Healthcare coverage affects survival of Thai lung cancer patients

Khiewngam K, Oranratnachai S, Kamprerasart K, Kunakorntham P, Sanvarinda P, Trachu N, et al.

Front Oncol . 2023 Mar; 13:1047644. PMID: 36895484

Background: Despite significant benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment in patients with -mutated NSCLC, access remains limited in Thailand and elsewhere. Methods: Retrospective analysis of patients...

Treatment outcomes of advanced hepatocellular carcinoma in real-life practice: Chemotherapy versus multikinase inhibitors

Oranratnachai S, Rattanasiri S, Sirachainan E, Tansawet A, Raunroadroong N, Mckay G, et al.

Cancer Med . 2022 Sep; 12(3):3046-3053. PMID: 36082831

Background: Multikinase inhibitors (MKIs) represent the main treatment options for advanced hepatocellular carcinoma (aHCC). However, accessibility in developing countries is limited. A chemotherapy, Fluorouracil and Oxaliplatin (FOLFOX), offers a less...

Gastrointestinal microbiota profile and clinical correlations in advanced EGFR-WT and EGFR-mutant non-small cell lung cancer

Saifon W, Sensorn I, Trachu N, Oranratnachai S, Charoenyingwattana A, Runcharoen C, et al.

BMC Cancer . 2022 Sep; 22(1):963. PMID: 36076157

Introduction: Difference in clinical responses to cancer therapy in each patient is from several factors. Gastrointestinal microbiota is one of the reasons. However, this correlation remains unknown. This study aims...

Characteristics of breast cancer patients tested for germline BRCA1/2 mutations by next-generation sequencing in Ramathibodi Hospital, Mahidol University

Oranratnachai S, Yamkaew W, Tunteeratum A, Sukarayothin T, Iemwimangsa N, Panvichien R

Cancer Rep (Hoboken) . 2022 Jul; 6(1):e1664. PMID: 35778884

Introduction: Germline mutations in BRCA1/2 are the most common cause of hereditary breast and ovarian cancer (HBOC) syndrome. Few studies published during the past decade reported the prevalence of germline...

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patients

Janpipatkul K, Trachu N, Watcharenwong P, Panvongsa W, Worakitchanon W, Metheetrairut C, et al.

Cancer Biomark . 2021 Apr; 31(3):281-294. PMID: 33896827

Background: Osimertinib is an epidermal growth factor receptor-tyrosine kinase inhibitor that specifically targets the T790M mutation in cancer.Unfortunately, most non-small cell lung cancer (NSCLC) patients develop osimertinib resistance. Currently, the...

Efficacy of First Line Systemic Chemotherapy and Multikinase Inhibitors in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis

Oranratnachai S, Rattanasiri S, Pooprasert A, Tansawet A, Reungwetwattana T, Attia J, et al.

Front Oncol . 2021 Apr; 11:654020. PMID: 33869060

Background: Hepatocellular carcinoma (HCC) is the third most fatal cancer, with a 5-year survival rate of 18%. Standard frontline-therapy is multikinase inhibitors (MKIs), but accessibility is still limited, particularly in...

10.

Lung Cancer in Thailand

Reungwetwattana T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, Cherntanomwong P

J Thorac Oncol . 2020 Nov; 15(11):1714-1721. PMID: 33148410

No abstract available.